+

WO2004086034A3 - Agents diagnostiques et therapeutiques pour maladies associees au recepteur adenosine a3 couple a la proteine g (adora3) - Google Patents

Agents diagnostiques et therapeutiques pour maladies associees au recepteur adenosine a3 couple a la proteine g (adora3) Download PDF

Info

Publication number
WO2004086034A3
WO2004086034A3 PCT/EP2004/002732 EP2004002732W WO2004086034A3 WO 2004086034 A3 WO2004086034 A3 WO 2004086034A3 EP 2004002732 W EP2004002732 W EP 2004002732W WO 2004086034 A3 WO2004086034 A3 WO 2004086034A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
adora3
diseases
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2004/002732
Other languages
English (en)
Other versions
WO2004086034A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Ralf Thiele
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Ralf Thiele
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts, Ralf Thiele filed Critical Bayer Healthcare Ag
Publication of WO2004086034A2 publication Critical patent/WO2004086034A2/fr
Publication of WO2004086034A3 publication Critical patent/WO2004086034A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne un ADORA3 humain qui est associé aux troubles cardiovasculaires, aux troubles urologiques, aux troubles du système endocrinien ou des hormones endocrines, aux maladies inflammatoires, aux maladies gastro-intestinales et hépatiques, aux troubles hématologiques, aux maladies respiratoires et aux troubles neurologiques. Cette invention concerne également des analyses permettant d'identifier des composés servant au traitement ou à la prévention de troubles cardiovasculaires, de troubles urologiques, de troubles du système endocrinien ou des hormones endocrines, de maladies inflammatoires, de maladies gastro-intestinales et hépatiques, de troubles hématologiques, de maladies respiratoires et de troubles neurologiques. Cette invention concerne également des composés qui se lient au récepteur ADORA3 et/ou qui activent ou inhibent l'activité du récepteur ADORA3, ainsi que des compositions pharmaceutiques qui renferment ces composés.
PCT/EP2004/002732 2003-03-28 2004-03-17 Agents diagnostiques et therapeutiques pour maladies associees au recepteur adenosine a3 couple a la proteine g (adora3) WO2004086034A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03006850 2003-03-28
EP03006850.6 2003-03-28

Publications (2)

Publication Number Publication Date
WO2004086034A2 WO2004086034A2 (fr) 2004-10-07
WO2004086034A3 true WO2004086034A3 (fr) 2005-04-28

Family

ID=33040918

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/002732 WO2004086034A2 (fr) 2003-03-28 2004-03-17 Agents diagnostiques et therapeutiques pour maladies associees au recepteur adenosine a3 couple a la proteine g (adora3)

Country Status (1)

Country Link
WO (1) WO2004086034A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101971762B1 (ko) 2012-08-09 2019-08-13 캔-파이트 바이오파마 리미티드 성기능장애의 치료에 사용하기 위한 a3 아데노신 수용체 리간드

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2309817T3 (es) * 2004-12-02 2008-12-16 Can-Fite Biopharma Ltd. Tratamiento de inflamacion.
CN110244057B (zh) * 2019-06-10 2020-05-12 浙江大学 Adora3在制备高级别浆液性卵巢癌诊断及预后试剂盒中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2264948A (en) * 1992-03-13 1993-09-15 Merck & Co Inc Human adenosine receptors
WO2002061087A2 (fr) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Peptides antigeniques destines a des recepteurs couples a la proteine g (gpcr), anticorps s'y rapportant, et systeme d'identification desdits peptides antigeniques
WO2003014137A1 (fr) * 2001-08-08 2003-02-20 Cv Therapeutics, Inc. Agonistes du recepteur adenosine a3

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2264948A (en) * 1992-03-13 1993-09-15 Merck & Co Inc Human adenosine receptors
WO2002061087A2 (fr) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Peptides antigeniques destines a des recepteurs couples a la proteine g (gpcr), anticorps s'y rapportant, et systeme d'identification desdits peptides antigeniques
WO2003014137A1 (fr) * 2001-08-08 2003-02-20 Cv Therapeutics, Inc. Agonistes du recepteur adenosine a3

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE AAGENESEQ 1994, XP002303206, Database accession no. AAR41527 *
DATABASE AAGENESEQ 4 March 2003 (2003-03-04), XP002303207, Database accession no. ABP81774 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2002, ROSI S ET AL: "THE ROLE OF ADENOSINE RECEPTORS IN THE TREATMENT OF NEUROINFLAMMATION WITH A NO - NSAID.", XP002305658, Database accession no. PREV200300380929 *
OKAMURA T ET AL: "1,2,4-Triazolo[5,1-i]purine Derivatives as Highly Potent and Selective Human Adenosine A3 Receptor Ligands", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 45, no. 17, 16 July 2002 (2002-07-16), pages 3703 - 3708, XP002222673, ISSN: 0022-2623 *
RIBEIRO J A ET AL: "Adenosine receptors in the nervous system: Pathophysiological implications.", PROGRESS IN NEUROBIOLOGY (OXFORD), vol. 68, no. 6, December 2002 (2002-12-01), pages 377 - 392, XP002287447, ISSN: 0301-0082 *
SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2002, 2002, 32ND ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE; ORLANDO, FLORIDA, USA; NOVEMBER 02-07, 2002, pages Abstract No. 884.7 URL - http://sf *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101971762B1 (ko) 2012-08-09 2019-08-13 캔-파이트 바이오파마 리미티드 성기능장애의 치료에 사용하기 위한 a3 아데노신 수용체 리간드

Also Published As

Publication number Publication date
WO2004086034A2 (fr) 2004-10-07

Similar Documents

Publication Publication Date Title
WO2005040828A3 (fr) Agents de diagnostic et de traitement des maladies associees au recepteur 49 couple aux proteines g (gpr49)
WO2004080373A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur 2 active par la proteinase (par2) couple aux proteines g
WO2004099782A3 (fr) Approche diagnostique et therapeutique des maladies associees au recepteur gpr39 (gpr39) couple a une proteine g
WO2004086034A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur adenosine a3 couple a la proteine g (adora3)
WO2004082568A3 (fr) Diagnostics et traitements contre des maladies associees au recepteur 5a du composant du complement (c5ar)
WO2004099783A3 (fr) Diagnostics et therapies destines a des maladies associees au recepteur ltb4 (ltb4) couple a la proteine g
WO2004081563A3 (fr) Moyens de diagnostic et therapeutiques pour des maladies associees a la phosphodiesterase 1a (pde1a)
WO2005040211A3 (fr) Composes destines au diagnostic et au traitement de maladies associees au recepteur 1 couple aux proteines g (gpr1)
WO2005040825A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 20 couple a la proteine g (gpr20)
WO2004082570A3 (fr) Diagnostics et traitements contre des maladies associees au recepteur d2 de la dopamine (drd2)
WO2005095972A3 (fr) Composes destines au diagnostic et au traitement de maladies associees au recepteur couple aux proteines g etb (etb)
WO2004106935A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur 103 couples aux proteines g (gpr103)
WO2004082571A3 (fr) Diagnostics et therapies pour maladies associees au recepteur 86 couple a la proteine g (gpr86)
WO2005059546A3 (fr) Diagnostics et therapeutique destines au traitement de maladies associees au recepteur couple aux proteines g 35 (gpr35)
WO2004099781A3 (fr) Approches diagnostique et therapeutique des maladies associees au recepteur rdc1 (rdc1) couple a une proteine g
WO2004086047A3 (fr) Agents diagnostiques et therapeutiques de maladies associees a adenosine a1 du recepteur couple a la proteine g (adora1)
WO2005106489A3 (fr) Diagnostics et therapies s'appliquant a des maladies associees aux recepteurs 5 des chimiokines c-c (ccr5)
WO2004082572A3 (fr) Diagnostics et therapies pour les maladies associees au recepteur 87 couple a la proteine g (gpr87)
WO2004086052A3 (fr) Produits de diagnostic et de therapeutique pour des maladies liees au recepteur de l'adenosine a2b couple a la proteine g (adora2b)
WO2004099248A3 (fr) Produits de diagnostic et de traitement de maladies associees au recepteur agtr2 couple aux proteines g (agtr2)
WO2005040829A3 (fr) Agents de diagnostic et de traitement des maladies associees au recepteur 17 couple aux proteines g (gpr17)
WO2004099772A3 (fr) Methodes diagnostiques et therapeutiques pour les maladies associees au recepteur agtr1a couple aux proteines g (agtr1a)
WO2005003779A3 (fr) Diagnostics et traitements therapeutiques des maladies associees au recepteur 3 couple a une proteine g specifique aux neurones sensoriels (snsr3)
WO2005095984A3 (fr) Compositions diagnostiques et therapeutiques pour des maladies associees au recepteur adrenergique alpha 2a couple a la proteine g (adra2a)
WO2004080372A3 (fr) Diagnostic et traitement de maladies associees au recepteur 4 active par la proteinase et couple aux proteines g (par 4)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载